Controlled-Release Otic Composition for Inner Ear Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for otic disorders face challenges such as the difficulty in delivering therapeutic agents to the inner ear due to its isolated environment and susceptibility to infections, requiring stringent sterility, and existing compositions often cause changes in ionic balance and discomfort, with systemic administration leading to toxicities and side effects.
Innovation Solution
Development of controlled-release compositions and devices that are sterilized and compatible with the inner ear environment, providing a controlled release of otic structure modulating agents or innate immune system modulating agents directly to the middle or inner ear, using auris-acceptable excipients and vehicles that minimize systemic toxicity and discomfort, and are designed to maintain homeostasis and adhere to otic surfaces.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic agents are administered systemically to treat otic disorders, then therapeutic efficacy is achieved, but systemic toxicities and side effects occur
Solution Approach 1:
The patent employs local administration of therapeutic agents directly to the middle ear space through myringotomy or tympanostomy tube delivery. This localized approach concentrates the therapeutic effect at the target site (otic structures) while minimizing systemic distribution, thereby achieving treatment efficacy without the broad systemic exposure that causes toxicities and side effects
Solution Approach 2:
The patent uses tympanostomy tubes or myringotomy sites as intermediary delivery pathways. These intermediaries provide direct access to the middle ear compartment, allowing therapeutic agents to be delivered precisely to the target site without requiring systemic circulation, thus avoiding the harmful effects of systemic administration
2Reliability
If existing otic compositions are administered to treat ear infections, then therapeutic effect is achieved, but changes in ionic balance and discomfort occur
Solution Approach 1:
The patent formulates therapeutic compositions with pH and ionic composition specifically matched to the middle ear environment (pH approximately 7.0-7.5, isotonic conditions). By adjusting these parameters to match physiological conditions, the composition achieves therapeutic effect while minimizing disruption to ionic balance and reducing discomfort or irritation to otic structures
Solution Approach 2:
The patent creates compositions that are homogeneous in their interaction with the middle ear environment, matching the ionic strength, pH, and osmolarity of native ear fluids. This homogeneity ensures that the therapeutic agent is delivered effectively while maintaining compatibility with the otic environment, avoiding the discomfort and ionic imbalance caused by non-compatible formulations
3Reliability
If frequent dosing is used to maintain therapeutic levels, then therapeutic efficacy is maintained, but dosing frequency and patient burden increase
Solution Approach 1:
The patent delivers a sufficient (excessive) amount of therapeutic agent directly to the middle ear space in a single administration. This ensures that therapeutic levels are maintained for an extended period without requiring frequent redosing, as the localized delivery ensures complete utilization of the administered dose at the target site
Solution Approach 2:
The patent establishes sustained therapeutic presence by delivering an adequate dose in advance through controlled-release mechanisms or sustained-release formulations. This preliminary adequate dosing ensures therapeutic efficacy is maintained over time without requiring frequent patient visits for additional dosing
4Reliability
If the inner ear environment is accessed for direct delivery, then therapeutic efficacy is improved, but sterility requirements and delivery difficulty increase
Solution Approach 1:
The patent uses the middle ear space as an intermediary compartment that is more accessible than the inner ear but still provides effective delivery to otic structures. The middle ear can be accessed through myringotomy or existing tympanostomy tubes, avoiding the need for direct inner ear puncture while maintaining therapeutic efficacy through proximity to target structures
Solution Approach 2:
The patent extracts the delivery route from the complex inner ear access pathway and simplifies it by utilizing the middle ear space as the delivery site. This extraction of the therapeutic agent delivery location from the deep inner ear to the more accessible middle ear reduces the complexity of the delivery procedure while maintaining effectiveness
Data Source
AI summary
Disclosed herein are compositions and methods for the treatment of otic disorders with otic structure modulating compositions administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and compositions onto or via perfusion into the targeted auris structure(s).